Boryung Launches Bone Disease Treatment 'Xbryk' in Korea

Developed by Samsung Bioepis
Sales and Marketing by Boryung

Boryung announced on August 4 that it officially launched 'Xbryk' (ingredient: denosumab), a bone disease treatment developed by Samsung Bioepis, in Korea on August 1.

Xbryk (active ingredient Denosumab), a bone disease treatment developed by Samsung Bioepis and marketed and sold by Boryung. Photo by Boryung

Xbryk is a biosimilar (biopharmaceutical generic) of Xgeva. It is used to prevent skeletal-related events (SRE) in cancer patients with bone metastases and to treat giant cell tumor of bone. Based on these indications, the global market size for denosumab is estimated at approximately 3.3 trillion KRW.

Following product approval in May, the signing of a domestic sales partnership agreement between Boryung and Samsung Bioepis in June, and the inclusion in the reimbursement list on August 1, full-scale supply of Xbryk has begun. Samsung Bioepis is responsible for development, production, and supply of Xbryk, while Boryung handles domestic sales and marketing.

Through the 'SB16' project, Xbryk demonstrated equivalent efficacy and safety to the original product in a global phase 3 clinical trial involving 456 postmenopausal women with osteoporosis from five countries, including 41 Korean participants. It was also confirmed that switching patients from the original product to Xbryk maintained the therapeutic effect.

Xbryk offers significantly improved storage convenience compared to the original. It can be stored at room temperature (25℃) for up to 60 days and then returned to refrigeration. Priced at 171,084 KRW per 1.7ml vial, it is the most economical denosumab-based bone disease treatment available. It is expected to reduce patients' medical expenses and improve access to treatment.

Boryung plans to accelerate prescription expansion by combining Samsung Bioepis's technological and quality strengths with its own expertise in oncology. The two companies have already demonstrated synergy through their partnership in oncology biosimilars. Last year, Onbevzi (ingredient: bevacizumab), one of their collaborative products, achieved sales of 45.2 billion KRW.

Jung Woongje, Head of Sales at Boryung, stated, "Xbryk is a high-quality biosimilar developed with Samsung Bioepis's proven technology, offering both storage convenience and cost-effectiveness. Through active sales and marketing, we aim to establish it as the optimal treatment choice for healthcare professionals and patients with bone diseases."

This content was produced with the assistance of AI translation services.